11 citations
,
September 2013 in “Journal of the Egyptian Women's Dermatologic Society (Print)” Various treatments exist for hair loss, but more research is needed for better options.
15 citations
,
August 2022 in “The Application of Clinical Genetics” This review describes the clinical presentation, diagnosis, and management of adrenomyeloneuropathy, including rehabilitative therapies and spasticity management, and reports no new clinical results.
January 2023 in “The Egyptian Journal of Hospital Medicine” This review discusses the use of dutasteride for treating androgenetic alopecia and reports no new clinical results.
June 2026 in “Journal of Cosmetic Dermatology” This study reported that microneedle-assisted delivery of PEGylated recombinant human fusion collagen significantly improved hair regrowth and density in an androgenetic alopecia mouse model and in a small clinical trial with AGA patients, suggesting potential efficacy and safety for this treatment approach.
May 2015 in “Hair transplant forum international” This review discusses androgenetic alopecia and reports no clinical findings; the authors highlight a need for further research.
March 2026 in “Actas Dermo-Sifiliográficas” In this study, dermatologists in Spain reported a shift in androgenetic alopecia treatment practices from 2019-2020 to 2024, with increased prescribing of oral minoxidil and oral dutasteride, and changes in antiandrogen choices for different patient groups.
June 2022 in “Journal of The European Academy of Dermatology and Venereology” This study reports no results yet and only indicates an ongoing randomized placebo-controlled trial investigating the effects of microneedling combined with topical dutasteride solution for treating androgenetic alopecia.
June 2020 in “Acta medica Philippina” This research review suggests that topical adenosine could improve hair thickness and user satisfaction in adults with androgenetic alopecia, with minimal side effects reported, but concludes that further studies are necessary to confirm these findings.
This article provides an overview of current treatments and alternative formulations for androgenic alopecia but reports no new clinical results.
September 2023 in “Journal of The American Academy of Dermatology” This study found that adolescents with androgenetic alopecia showed distinct hormonal profiles between boys and girls, with concurrent metabolic dysfunction present in both sexes, highlighting the need for sex-specific diagnosis and management approaches.
June 2023 in “Drugs & Therapy Perspectives” This study discusses treatment options for androgenetic alopecia, highlighting that while available therapies include approved and off-label pharmacological agents and non-pharmacological treatments, there is still limited evidence-based guidance on managing this common hair loss disorder.
16 citations
,
September 2014 in “International Journal of Biological Markers” This study found that the less common CAG-rs4045402 and GGN-rs3138869 polymorphisms were more frequent in patients with post-finasteride syndrome and androgenetic alopecia, suggesting a genetic predisposition to AGA development.
47 citations
,
December 2000 in “Archives of Dermatological Research” This study found that women with androgenetic alopecia showed higher levels of certain hormones and lower levels of sex hormone-binding globulin than healthy controls, potentially linking these factors to alopecia severity.
24 citations
,
January 2018 in “Indian Journal of Dermatology, Venereology and Leprology” This review discusses advances in molecular biology and genetics related to androgenetic alopecia and reports no new clinical results.
August 2026 in “JAMA Dermatology” This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.
51 citations
,
January 2012 in “Annals of Dermatology” This review discusses characteristics of androgenetic alopecia in Asian patients and includes algorithmic management guidelines, but reports no new clinical findings.
January 2026 in “European Journal of Dermatology” This article examines the use of legal amphetamines by French political figures from the Liberation to the 1960s, highlighting their impact on health and their prevalence among Communist activists, influenced by habits from the Resistance.
May 2025 in “The Journal of Dermatology” This article includes visual documentation of eyebrow morphology during a disease course, but reports no new research findings.
February 2025 in “Journal of the American Academy of Dermatology” People with androgenetic alopecia may have a higher risk of peripheral venous disorders.
August 2014 in “Journal of clinical & experimental dermatology research” This study outlines a hair regrowth treatment targeting hair follicle stem cells, 5-alpha reductase pathway, and microinflammation using PDGF and VEGF, but reports no clinical results.
This study found a significant association between androgenetic alopecia and metabolic syndrome, with AGA patients showing higher BMI, waist circumference, blood glucose, and cholesterol levels compared to controls.
April 2024 in “European Journal of Dermatology” This study suggests that the PPP2R3C gene may confer susceptibility to psoriatic arthritis and psoriasis vulgaris in Chinese patients, with additional possible associations involving IL-23R, ERN1, IFIH1, and KIF3A genes.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review explores the complex pathophysiology of androgenetic alopecia, highlighting genetic factors, androgen metabolism, and emerging therapies such as platelet-rich plasma and low-level laser therapy, but notes that no ultimate cure exists and treatments focus on slowing progression and promoting hair growth.
March 2026 in “Editora Pasteur eBooks” This study conducted a narrative literature review on androgenetic alopecia, highlighting the clinical diagnosis and management strategies, including minoxidil and 5-alpha-reductase inhibitors for men, and antiandrogens for women, along with the use of aesthetic procedures like microneedling as complementary therapies.
1 citations
,
May 1999 in “Journal of The European Academy of Dermatology and Venereology” This article provides guidelines for diagnosing and managing androgenetic alopecia, highlighting that medical treatments like finasteride and minoxidil can effectively halt and reverse the condition's progression in many cases.
October 2023 in “Dermatology practical & conceptual” In this study, AMD was observed more frequently in AGA patients, and a higher monocyte/HDL ratio was associated with increased AMD severity, especially in men.
1 citations
,
January 2023 in “The FASEB Journal” This study found that circAGK was highly expressed in AGA patients and promoted dermal papilla cell apoptosis, suggesting it as a potential target for treating androgen alopecia.
1 citations
,
August 2002 in “Zeitschrift für Hautkrankheiten” Male androgenetic alopecia involves hair follicle miniaturization due to DHT, with potential treatments using inhibitors and blockers.
This study found that arginine deficiency in androgenetic alopecia patients is linked to increased oxidative stress and impaired hair follicle regeneration, with targeted arginine supplementation showing promise as a therapeutic strategy.
37 citations
,
January 2005 in “Dermatology Online Journal” In this study, researchers observed a significant association between female androgenetic alopecia and coronary artery disease in women under 55, supporting a link similar to that seen in men.